CEO of ViiV Healthcare said: “The FDA approval of Juluca marks an important milestone in our commitment to deliver innovative advances in HIV care by providing new treatment options that ...
ViiV is also working with Janssen to develop a once-monthly injectable HIV combo regimen, which recently reported positive phase 3 trial results. George Underwood 9 April, 2019 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback